Pioneering in the field of respiratory allergies for more than a century, we've embarked on a mission to help more people, with more solutions, more efficiently.
News
- Post date09/17/2025ALK and GenSci partner to expand the AIT market in China
- Post date09/08/2025Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray
- Post date09/04/2025ALK expands the Executive Leadership Team to include key commercial regions
- Post date08/21/2025Six-month interim report (Q2) 2025 (unaudited)
- Post date08/14/2025Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
- Post date08/12/2025ALK upgrades its full-year revenue outlook
- Post date07/21/2025ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
- Post date07/18/2025EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
- Post date06/26/2025First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
For more than a 100 years, ALK has been at the forefront of allergy research and treatment. We're on a mission to help even more people globally, reaching 5 million people a year by 2030.
Allergy solutions
Allergy is caused by an overreaction of the body’s immune system to substances that in most cases would otherwise be harmless. Learn about the chronic disease, diagnosis, and treatment options.
Sustainability
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.
Careers
Become part of a team that is passionate about making a difference for people living with allergy. In our global company, we share expertise and knowledge across boarders and cultures and have a focus on continuous employee development.